Oral versus vaginal progestogens in women with recurrent miscarriages

Efficacy of oral versus vaginal progestogens in the maintenance of early pregnancy in women with recurrent miscarriages

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230117057148N1

Enrollment

108

Registered

2023-04-06

Start date

2020-04-02

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent miscarriages. Spontaneous abortion

Interventions

Intervention 1: Interventional Group 1: This group will be given oral progestogens in a dose of 10mg twice a day in morning and evening after meals for 12 weeks. Efficacy will be measured by continuat

Eligibility

Sex/Gender

Female

Age

16 Years to 40 Years

Inclusion criteria

Inclusion criteria: Pregnancy Aged 16-40 years, A history of at least three recurrent miscarriages At or less than 7 weeks of gestational age

Exclusion criteria

Exclusion criteria: Threatened miscarriage, Breast carcinoma Structural uterine abnormality distorting the cavity, Absence of fetal cardiac activity (missed abortion), Contraindications to progestron use (e.g. allergy to progesterone) Inadequate treatment compliance

Design outcomes

Primary

Measure	Time frame
Pregnancy. Timepoint: 12 weeks of gestation. Method of measurement: ultrasound.	—

Countries

Pakistan

Contacts

Public ContactDr Laiyla Shinwari

Lady Reading hospital

drlailakhan@yahoo.com+92 332 9022886

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026